MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41416-025-03286-w

Медицинская библиотека · British journal of cancer · 2025

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.

Yamamoto Noboru, Yan Dong, Ganju Vinod, Hou Xinfang, Pan Hongming, Shan Jianzhen, Wang Liwei, Kim Sang-We, Richardson Gary, Sanborn Rachel E, Zhang Jingdong, Xiang Ziyong, Wang Wenjia, Shi Zhe, Zhang Ling, Wang Yaolin, Xu Rui-Hua

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеКлиническое исследование I фазыПеревод пока не подготовлен

Аннотация

BACKGROUND

Garsorasib (D-1553), a highly selective, oral KRASG12C inhibitor, has shown clinical efficacy in NSCLC and CRC and is under evaluation in pancreatic cancer.

METHODS

Pancreatic cancer patients with KRAS G12C mutation were enroled and received garsorasib 600 mg twice daily treatment in two international, multicenter, open-label phase 1/2 trials (NCT04585035 and NCT05383898) with similar eligibility criteria. Their data were pooled for analyses of efficacy and safety endpoints.

RESULTS

As of April 30, 2024, 24 KRAS G12C-mutated pancreatic cancer patients were enroled with a median follow-up of 8.9 months (range 1.1-22.9). Among 22 evaluable patients, the confirmed objective response rate (ORR) was 45.5% (95% CI, 24.4 to 67.8) with a median duration of response (DOR) of 6.4 months (95% CI, 4.2 to 16.4). The median progression-free survival (PFS) was 7.6 months (95% CI, 3.3 to 8.5) and the 6-month OS rate was 79.2% (95% CI, 57.0, 90.8). Treatment-related adverse events (TRAEs) occurred in 18 (75.0%) patients, including 6 (25.0%) with grade ≥3 events. No TRAEs led to treatment discontinuation. The safety profile was consistent with previous reports of garsorasib.

CONCLUSION

Garsorasib demonstrated encouraging antitumor activity and a tolerable safety profile in patients with KRAS G12C-mutated advanced pancreatic cancer.

Для цитирования: Yamamoto Noboru, Yan Dong, Ganju Vinod, Hou Xinfang, Pan Hongming, Shan Jianzhen, Wang Liwei, Kim Sang-We, Richardson Gary, Sanborn Rachel E, Zhang Jingdong, Xiang Ziyong, Wang Wenjia, Shi Zhe, Zhang Ling, Wang Yaolin, Xu Rui-Hua. Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.. British journal of cancer. 2025. DOI: 10.1038/s41416-025-03286-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.